AKT1 polymorphisms were associated with clinical outcomes in patients with lung25 and gastric cancers26; however, a separate study found that AKT1 polymorphisms are rare and not valuable as biomarkers for bladder cancer management.27 This evidence concerns the gene AKT1 and urinary bladder carcinoma.